Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozurdex in Lieu of Oral Corticosteroids for Uveitis
NCT02049476Phase 4Completed
- Sponsor
- Johns Hopkins University
- Start
- Jan 2014
- Primary completion
- Jun 2018
- Modality
- Implantable Devices, Implantable Hydrogels, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ozurdex in intermediate uveitis (IU) and posterior uveitis, sponsored by Johns Hopkins University. Primary endpoint: Number of Participants With Absence of Intraocular Inflammation at 6 months. Started Jan 2014; status: completed.
02
Drugs
ozurdex
03
Conditions
intermediate uveitis (IU)posterior uveitis
Beyond the preview
Go deeper on NCT02049476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049476.